https://www.selleckchem.com/pr....oducts/golvatinib-e7
A third factor identified was consensus among stakeholders on the need to address AMR and their cooperation in the design and implementation of measures.The ganglioside GD2 is an important target in childhood cancer. Nevertheless, the only therapy targeting GD2 that is approved to date is the monoclonal antibody dinutuximab, which is used in the therapy of neuroblastoma. The relevance of GD2 as a target in other tumor entities remains to be elucidated. Here, we analyzed the expression of GD2 in different pediatric tumor entitie
Respect!
Kommentar
Delen
